Economy

China’s GDP, Buyback Plans Fuel Asia Stock Gains: Markets Wrap

Asian equities saw a boost as investors analyzed China's strong economic data and the announcement of a new stock buyback program by the country's central bank. Shares in China and

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.

Lasted Economy

Should You Buy Roku Stock After Its Partnership With Amazon?

Roku's recent partnership with Amazon has elevated the streaming specialist's appeal in the market. Despite facing challenges, Roku's long-term prospects

Iran holds funeral procession for top commanders killed in Israeli strikes

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.Iran Holds

Would Investing $10K in the Magnificent 7 Stocks in 2023 Have Made You Rich?

The Magnificent 7 stocks have been dominating the headlines in recent years due to their incredible returns. Amazon, Google parent

US multinationals on track for minimum tax reprieve after G7 deal

The recent agreement reached by the world’s leading economies to exempt US’s largest companies from paying more corporate tax overseas

Missing the Mark: When Punishment Reinforces the Wrong Behavior

Secretary Duffy's Dangerous Path: A Return to Blame in Aviation Safety In a recent NBC Nightline interview, Secretary of Transportation

Grant Cardone Warns Americans Are Stuck In Homes They Can’t Sell

Real estate investors have faced numerous challenges in the past two years, with high interest rates impacting transactions and prompting

Traders bet on interest rate cuts from Jay Powell’s successor at the Fed

Traders are increasingly placing their bets on US interest rate cuts following the announcement that Jay Powell will be leaving

Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush

Wedbush analyst Laura Chico recently adjusted the firm's price target on Edgewise Therapeutics (EWTX) from $40 to $35, while maintaining